Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors
Lisa Bodei(European Institute of Oncology), Irvin M. Modlin(Yale University), Chiara Maria Grana(Ripamonti), Christopher Lepensky(Yale University), Richard P. Baum(Hessische Hochschule für Polizei und Verwaltung), Giovanni Paganelli(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Ignat Drozdov(ING Direct), Dik J. Kwekkeboom(Erasmus MC), Mark Kidd(Wren Laboratories (United States)), Eric P. Krenning(Cyclotron (Netherlands)), Marta Cremonesi(European Institute of Oncology)
Cited by 465
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Gastroenteropancreatic neuroendocrine tumours
|The Lancet Oncology|2008|1.8k
Plasma MicroRNA Profiling Reveals Loss of Endothelial MiR-126 and Other MicroRNAs in Type 2 Diabetes
|Circulation Research|2010|1.5k
Treatment With the Radiolabeled Somatostatin Analog [ <sup>177</sup> Lu-DOTA <sup>0</sup> ,Tyr <sup>3</sup> ]Octreotate: Toxicity, Efficacy, and Survival
|Journal of Clinical Oncology|2008|1.4k